Johnson & Johnson announced Tuesday that it will resume the distribution of its COVID-19 vaccine in Europe after the European Union’s (EU) medical regulator approved of the same but with a safety warning, per Reuters.
The European Medicines Agency (EMA) recommended adding a warning about rare blood clots with low blood platelet count to the vaccine’s product label, citing that the benefits of the one-dose shot outweigh its risks.
J&J Chief Scientific Officer Paul Stoffels said: “It’s an extremely rare event. We hope by making people aware as well as putting clear diagnostic and therapeutic guidance in place that we can restore the confidence in our vaccine.”
J&J said it would fulfill its commitments to ship 200 million doses in Europe and 100 million in the United States.
At the time of writing, the S&P 500 futures trade 0.08% lower at 4,125 while the US dollar holds onto the recovery gains above 91.00.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.